Sunday, September 21, 2014 Last update: 8:33 AM - All Company Technology News Since 1996

Provectus Biopharmaceuticals’ PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society of Clinical Oncology (ASCO) Annual Meeting

Companies mentioned in this article: Provectus Biopharmaceuticals, Inc.

KNOXVILLE, Tenn. -- (BUSINESS WIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (, a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational drug PV-10 will be featured in a presentation by investigators from Moffitt Cancer Center in a Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL, May 30-June 3, 2014. The time and date of the presentation are expected to become available on the ASCO website,, on April 21, 2014.

The poster, based upon abstract #9028, is entitled "Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions," and is authored by Amod Sarnaik, MD and colleagues of Moffitt.

Craig Dees, PhD, CEO of Provectus said, "We value our relationship with Moffitt greatly, and we are excited by the assessment Dr. Sarnaik has made on clinical and immunologic activity of intralesional PV-10.”

Provectus has recently submitted an application to the FDA for breakthrough therapy designation for PV-10 based on the results from its Phase 2 clinical study of melanoma and is researching its efficacy for other indications.

About Moffitt Cancer Center

Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer since 1999. For more information, visit, and follow the Moffitt momentum on Facebook, Twitter and YouTube.

About Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, For additional information about Provectus please visit the Company's website at or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Copyright © Business Wire 2014

Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, CFO, COO
866-594-5999 #30
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, SVP – Investor Relations
Bill Gordon – Media Relations